Back to School: How biopharma can reboot drug development. Access exclusive analysis here

rhuMAb-VEGF: Phase II

In a 99-patient, open label trial of rhuMAb-VEGF in combination with carboplatin and paclitaxel, 22 percent of

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE